CoChat
Sign Up
Cited by 1,074Acute Lymphoblastic Leukemia researchLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Acute lymphoblastic leukaemia

Open access
Inaba, Hiroto, Greaves, Mel, Mullighan, Charles G·2013·The Lancet
DOI 10.1016/s0140-6736(12)62187-4PMC PMC3816716
Open this paper in CoChat — free account

Abstract

Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles. Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratification by biological features of leukaemic cells and response to treatment, treatment modification based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care. However, innovative approaches are needed to further improve survival while reducing adverse effects. Prognosis remains poor in infants and adults. Genome-wide profiling of germline and leukaemic cell DNA has identified novel submicroscopic structural genetic changes and sequence mutations that contribute to leukaemogenesis, define new disease subtypes, affect responsiveness to treatment, and might provide novel prognostic markers and therapeutic targets for personalised medicine.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(12)62187-4

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ALL patients are treated with a combination of ~10 different chemotherapy agents through several phases lasting 2-3 years.

    “ALL patients are treated with a combination of ~10 different chemotherapy agents through several phases lasting 2–3 years (Inaba et al., 2013; Pui, Robison, & Look, 2008; Pui et al., 2009).”

    From Brain structure, working memory and response inhibition in childhood leukemia survivors (2017) · cites this paper as Inaba et al., 2013

    The Treatment section says ALL treatment typically spans 2–2.5 years in three phases and uses combination chemotherapy. It does not specify approximately 10 different agents, and its descriptions of the phases do not establish that number. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • The bulk (83%) of our survivors were diagnosed between 2 and 6 years of age.

    “However, the bulk (83%) of our survivors were diagnosed between 2 and 6 years of age, which corresponds to the age of peak ALL incidence (Inaba et al., 2013; National Cancer Institute 2015).”

    From Brain structure, working memory and response inhibition in childhood leukemia survivors (2017) · cites this paper as Inaba et al., 2013

  • Incidence of ALL is higher in boys than in girls, and boys require longer treatment than girls due to sex-specific risk factors for ALL relapse.

    “Secondly, sex modulates disease‐ and treatment‐specific factors: incidence of ALL is higher in boys than in girls (Inaba et al., 2013; National Cancer Institute 2015; Pui & Evans, 2013; Pui et al., 1999; Sather, Miller, Nesbit, Heyn, & Hammond, 1981), and boys require longer treatment (~2.5 years) than girls (~2 years) due to sex‐specific risk factors for ALL relapse (Brecher et al., 1986; Tiedem”

    From Brain structure, working memory and response inhibition in childhood leukemia survivors (2017) · cites this paper as Inaba et al., 2013

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 145

  1. [2]Pui CH Robison LL Look AT Acute lymphoblastic leukaemia Lancet 2008 371 1030 43 18358930
  2. [3]Stanulla M Schrappe M Treatment of childhood acute lymphoblastic leukemia Semin Hematol 2009 46 52 63 19100368
  3. [4]Hunger SP Lu X Devidas M Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children’s Oncology Group J Clin Oncol 2012 PMC3383113 22412151
  4. [5]Bassan R Hoelzer D Modern therapy of acute lymphoblastic leukemia J Clin Oncol 2011 29 532 43 21220592
  5. [6]Pui CH Campana D Pei D Treating childhood acute lymphoblastic leukemia without cranial irradiation N Engl J Med 2009 360 2730 41 19553647 PMC2754320
  6. [7]Pieters R Schrappe M De Lorenzo P A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial Lancet 2007 370 240 50 17658395
  7. [8]Greaves MF Wiemels J Origins of chromosome translocations in childhood leukaemia Nature Rev Cancer 2003 3 639 49 12951583
  8. [9]Greaves MF Aetiology of acute leukaemia Lancet 1997 349 344 49 9024390
  9. [10]Greaves MF Maia AT Wiemels JL Ford AM Leukemia in twins: lessons in natural history Blood 2003 102 2321 33 12791663
  10. [11]Greaves M Infection, immune responses and the aetiology of childhood leukaemia Nat Rev Cancer 2006 6 193 203 16467884
  11. [12]Preston DL Kusumi S Tomonaga M Cancer incidence in atomic bomb survivors. Part III: Leukemia, lymphoma and multiple myeloma, 1950–1987 Radiat Res 1994 137 Suppl S68 S97 8127953
  12. [13]Doll R Wakeford R Risk of childhood cancer from fetal irradiation Br J Radiol 1997 70 130 39 9135438
  13. [14]Kendall G Little MP Wakeford R Numbers and proportions of leukemias in young people and adults induced by radiation of natural origin Leuk Res 2011 35 1039 43 21334745 PMC3998761
  14. [15]Schüz J Exposure to extremely low-frequency magnetic fields and the risk of childhood cancer: update of the epidemiological evidence Progr Biophysics Mol Biol 2011 107 339 42 21946043
  15. [17]Kinlen L Evidence for an infective cause of childhood leukaemia: comparison of a Scottish New Town with nuclear reprocessing sites in Britain Lancet 1988 ii 1323 27 2904050
  16. [18]Greaves MF Speculations on the cause of childhood acute lymphoblastic leukemia Leukemia 1988 2 120 25 3278171
  17. [19]Kinlen LJ Epidemiological evidence for an infective basis in childhood leukaemia Br J Cancer 1995 71 1 5 7819022 PMC2033475
  18. [20]Kinlen L Doll R Population mixing and childhood leukaemia: Fallon and other US clusters Br J Cancer 2004 91 1 3 15226760 PMC2364755
  19. [22]Kroll ME Draper GJ Stiller CA Murphy MFG Childhood leukemia incidence in Britain, 1974–2000: time trends and possible relation to influenza epidemics J Natl Cancer Inst 2006 98 417 20 16537835
  20. [23]Ford AM Palmi C Bueno C The TEL-AML1 leukemia fusion gene dysregulates the TGFβ pathway in early B lineage progenitor cells J Clin Invest 2009 119 826 36 19287094 PMC2662549
  21. [24]Taylor GM Birch JM Henderson ES Lister TA Greaves MF The hereditary basis of human leukemia Leukemia 6 Philadelphia WB Saunders 1996 210 45
  22. [25]Hasle H Clemmensen IH Mikkelsen M Risks of leukaemia and solid tumours in individuals with Down’s syndrome Lancet 2000 355 165 69 10675114
  23. [26]Vijayakrishnan J Houlston RS Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis Haematologica 2010 95 1405 14 20511665 PMC2913091
  24. [27]Papaemmanuil E Hosking FJ Vijayakrishnan J Loci on 7p12.2, 10q21.2 and 14q11. 2 are associated with risk of childhood acute lymphoblastic leukemia Nat Genet 2009 41 1006 10 19684604 PMC4915548
  25. [28]Trevino LR Yang W French D Germline genomic variants associated with childhood acute lymphoblastic leukemia Nat Genet 2009 41 1001 05 19684603 PMC2762391
  26. [29]Sherborne AL Hosking FJ Prasad RB Variation in CDKN2A at 9p21. 3 influences childhood acute lymphoblastic leukemia risk Nat Genet 2010 42 492 94 20453839 PMC3434228
  27. [30]Yang W Trevino LR Yang JJ ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence Leukemia 2010 24 894 96 20054350 PMC4607263
  28. [31]Yang JJ Cheng C Yang W Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia J Am Med Assoc 2009 301 393 403 PMC2664534 19176441
  29. [32]Harrison CJ Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia Br J Haematol 2009 144 147 56 19006567
  30. [33]Mullighan CG Goorha S Radtke I Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia Nature 2007 446 758 64 17344859
  31. [34]Mullighan CG Miller CB Radtke I BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros Nature 2008 453 110 4 18408710
  32. [35]Mullighan CG Zhang J Harvey RC JAK mutations in high-risk childhood acute lymphoblastic leukemia Proc Natl Acad Sci U S A 2009 106 9414 8 19470474 PMC2695045
  33. [36]Russell LJ Capasso M Vater I Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia Blood 2009 114 2688 98 19641190
  34. [37]Mullighan CG Collins-Underwood JR Phillips LA Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia Nat Genet 2009 41 1243 6 19838194 PMC2783810
  35. [38]Mullighan CG Zhang J Kasper LH CREBBP mutations in relapsed acute lymphoblastic leukaemia Nature 2011 471 235 9 21390130 PMC3076610
  36. [39]Kuiper RP Schoenmakers EF van Reijmersdal SV High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression Leukemia 2007 21 1258 66 17443227
  37. [40]Kawamata N Ogawa S Zimmermann M Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray Blood 2008 111 776 84 17890455 PMC2200831
  38. [41]Strefford JC Worley H Barber K Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization Oncogene 2007 26 4306 18 17237825
  39. [42]Van Vlierberghe P Homminga I Zuurbier L Cooperative genetic defects in TLX3 rearranged pediatric T-ALL Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2008 22 762 70 18185524
  40. [43]van Vlierberghe P Meijerink JP Lee C A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia Leukemia 2006 20 1245 53 16673019
  41. [45]Virely C Moulin S Cobaleda C Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia Leukemia 2010 24 1200 4 20393504
  42. [46]Iacobucci I Storlazzi CT Cilloni D Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell’Adulto Acute Leukemia Working Party (GIMEMA AL WP) Blood 2009 114 2159 67 19589926
  43. [48]Den Boer ML van Slegtenhorst M De Menezes RX A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study Lancet Oncol 2009 10 125 34 19138562 PMC2707020
  44. [49]Yoda A Yoda Y Chiaretti S Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia Proc Natl Acad Sci U S A 2010 107 252 57 20018760 PMC2806782
  45. [50]Hertzberg L Vendramini E Ganmore I Down syndrome acute lymphoblastic leukemia: a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the iBFM Study Group Blood 2010 115 1006 17 19965641
  46. [51]Harvey RC Mullighan CG Chen IM Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia Blood 2010 115 5312 21 20139093 PMC2902132
  47. [52]Levine RL Gilliland DG Myeloproliferative disorders Blood 2008 112 2190 8 18779404 PMC2962533
  48. [53]Buitenkamp TD Pieters R Gallimore NE Outcome in children with Down’s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations Leukemia 2012 26 2204 11 22441210
  49. [54]Roberts KG Morin RD Zhang J Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia Cancer Cell 2012 22 153 66 22897847 PMC3422513
  50. [55]Moorman AV Ensor HM Richards SM Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial Lancet Oncol 2010 11 429 38 20409752
  51. [56]Harewood L Robinson H Harris R Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases Leukemia 2003 17 547 53 12646943
  52. [57]Robinson HM Harrison CJ Moorman AV Chudoba I Strefford JC Intrachromosomal amplification of chromosome 21 (iAMP21) may arise from a breakage-fusion-bridge cycle Genes Chromosomes Cancer 2007 46 318 26 17243167
  53. [58]Attarbaschi A Mann G Panzer-Grumayer R Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials J Clin Oncol 2008 26 3046 50 18565891
  54. [59]Raimondi SC Pui CH Head DR Rivera GK Behm FG Cytogenetically different leukemic clones at relapse of childhood acute lymphoblastic leukemia Blood 1993 82 576 80 8329712
  55. [60]Mullighan CG Phillips LA Su X Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia Science 2008 322 1377 80 19039135 PMC2746051
  56. [61]Yang JJ Bhojwani D Yang W Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia Blood 2008 112 4178 83 18768390 PMC2581992
  57. [62]Kawamata N Ogawa S Seeger K Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia Int J Oncol 2009 34 1603 12 19424578
  58. [63]Hof J Krentz S van Schewick C Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia J Clin Oncol 2011 29 3185 93 21747090
  59. [64]Inthal A Zeitlhofer P Zeginigg M CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia Leukemia 2012 10.1038/leu.2012.60 PMC4194312 22388726 · DOI
  60. [65]Zhang J Mullighan CG Harvey RC Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group Blood 2011 118 3080 7 21680795 PMC3175785
  61. [66]Rothenberg EV Moore JE Yui MA Launching the T-cell-lineage developmental programme Nat Rev Immunol 2008 8 9 21 18097446 PMC3131407
  62. [67]Coustan-Smith E Mullighan CG Onciu M Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia Lancet Oncol 2009 10 147 56 19147408 PMC2840241
  63. [69]Van Vlierberghe P Palomero T Khiabanian H PHF6 mutations in T-cell acute lymphoblastic leukemia Nat Genet 2010 42 338 42 20228800 PMC2847364
  64. [70]Yang JJ Cheng C Devidas M Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia Nat Genet 2011 43 237 41 21297632 PMC3104508
  65. [71]Xu H Cheng C Devidas M ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia J Clin Oncol 2012 30 751 7 22291082 PMC3295551
  66. [72]Schafer ES Hunger SP Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults Nat Rev Clin Oncol 2011 8 417 24 21629213
  67. [73]Boissel N Auclerc MF Lheritier V Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials J Clin Oncol 2003 21 774 80 12610173
  68. [74]de Bont JM Holt B Dekker AW van der Does-van den Berg A Sonneveld P Pieters R Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands Leukemia 2004 18 2032 5 15483674
  69. [75]Stock W La M Sanford B What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies Blood 2008 112 1646 54 18502832 PMC2518876
  70. [76]Pui CH Pei D Campana D Improved prognosis for older adolescents with acute lymphoblastic leukemia J Clin Oncol 2011 29 386 91 21172890 PMC3058285
  71. [77]Campana D Minimal residual disease monitoring in childhood acute lymphoblastic leukemia Curr Opin Hematol 2012 22525580
  72. [78]Borowitz MJ Devidas M Hunger SP Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study Blood 2008 111 5477 85 18388178 PMC2424148
  73. [79]Conter V Bartram CR Valsecchi MG Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study Blood 2010 115 3206 14 20154213
  74. [80]Schrappe M Valsecchi MG Bartram CR Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study Blood 2011 118 2077 84 21719599
  75. [81]Basso G Veltroni M Valsecchi MG Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow J Clin Oncol 2009 27 5168 74 19805690
  76. [82]Gokbuget N Kneba M Raff T Adults with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies Blood 2012 22442346
  77. [83]Stow P Key L Chen X Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia Blood 2010 115 4657 63 20304809 PMC2890183
  78. [84]Coustan-Smith E Song G Clark C New markers for minimal residual disease detection in acute lymphoblastic leukemia Blood 2011 117 6267 76 21487112 PMC3122946
  79. [85]Inaba H Pui CH Glucocorticoid use in acute lymphoblastic leukaemia Lancet Oncol 2010 11 1096 106 20947430 PMC3309707
  80. [86]Bostrom BC Sensel MR Sather HN Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group Blood 2003 101 3809 17 12531809
  81. [87]Mitchell CD Richards SM Kinsey SE Lilleyman J Vora A Eden TO Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial Br J Haematol 2005 129 734 45 15952999
  82. [90]Igarashi S Manabe A Ohara A No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children’s Cancer Study Group L95-14 protocol J Clin Oncol 2005 23 6489 98 16170158
  83. [92]Pui CH Mullighan CG Evans WE Relling MV Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012 120 1165 74 22730540 PMC3418713
  84. [94]Silverman LB Supko JG Stevenson KE Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia Blood 2010 115 1351 3 20007809 PMC2826760
  85. [95]Silverman LB Gelber RD Dalton VK Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01 Blood 2001 97 1211 8 11222362
  86. [96]Willer A Gerss J Konig T Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials Blood 2011 118 5774 82 21940824
  87. [97]Yang L Panetta JC Cai X Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia J Clin Oncol 2008 26 1932 9 18421047
  88. [98]Kawedia JD Liu C Pei D Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia Blood 2012 119 1658 64 22117041 PMC3286344
  89. [99]Schultz KR Bowman WP Aledo A Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study J Clin Oncol 2009 27 5175 81 19805687 PMC2773475
  90. [100]Ravandi F O’Brien S Thomas D First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia Blood 2010 116 2070 7 20466853 PMC4081177
  91. [101]Ottmann O Dombret H Martinelli G Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study Blood 2007 110 2309 15 17496201
  92. [102]Porkka K Koskenvesa P Lundan T Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia Blood 2008 112 1005 12 18477770
  93. [103]Whitehead VM Vuchich MJ Lauer SJ Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study Blood 1992 80 1316 23 1381244
  94. [104]Rots MG Pieters R Peters GJ Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia Blood 1999 93 1677 83 10029597
  95. [105]French D Yang W Cheng C Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia Blood 2009 113 4512 20 19066393 PMC2680361
  96. [106]Trevino LR Shimasaki N Yang W Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects J Clin Oncol 2009 27 5972 8 19901119 PMC2793040
  97. [107]Ramsey LB Bruun GH Yang W Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition Genome Res 2012 22 1 8 22147369 PMC3246196
  98. [109]Mikkelsen TS Sparreboom A Cheng C Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial J Clin Oncol 2011 29 1771 8 21444869 PMC3107765
  99. [110]Skarby TV Anderson H Heldrup J Kanerva JA Seidel H Schmiegelow K High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia Leukemia 2006 20 1955 62 16990760
  100. [111]Seibel NL Steinherz PG Sather HN Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group Blood 2008 111 2548 55 18039957 PMC2254538
  101. [112]Matloub Y Bostrom BC Hunger SP Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group Blood 2011 118 243 51 21562038 PMC3138679
  102. [113]Mattano LA Jr Devidas M Nachman JB Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial Lancet Oncol 2012 13 906 15 22901620 PMC3448283
  103. [114]Balduzzi A Valsecchi MG Uderzo C Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study Lancet 2005 366 635 42 16112299
  104. [115]Marks DI Wang T Perez WS The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission Blood 2010 116 366 74 20404137 PMC2913452
  105. [116]Leung W Campana D Yang J High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia Blood 2011 118 223 30 21613256 PMC3138677
  106. [117]Eapen M Rubinstein P Zhang MJ Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study Lancet 2007 369 1947 54 17560447
  107. [118]Eapen M Rocha V Sanz G Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis Lancet Oncol 2010 11 653 60 20558104 PMC3163510
  108. [119]Bader P Kreyenberg H Henze GH Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group J Clin Oncol 2009 27 377 84 19064980
  109. [120]Leung W Pui CH Coustan-Smith E Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia Blood 2012 PMC3398757 22517895
  110. [121]Schrappe M Hunger SP Pui CH Outcomes after induction failure in childhood acute lymphoblastic leukemia N Engl J Med 2012 366 1371 81 22494120 PMC3374496
  111. [122]Dreyer ZE Dinndorf PA Camitta B Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children’s Oncology Group J Clin Oncol 2011 29 214 22 21135279 PMC3058277
  112. [123]Mann G Attarbaschi A Schrappe M Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study Blood 2010 116 2644 50 20592248
  113. [124]Harms DO Gobel U Spaar HJ Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92 Blood 2003 102 2736 40 12843002
  114. [125]Vora A Mitchell CD Lennard L Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial Lancet 2006 368 1339 48 17046466
  115. [126]Stork LC Matloub Y Broxson E Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children’s Oncology Group CCG-1952 clinical trial Blood 2010 115 2740 8 20124218 PMC2854423
  116. [127]Relling MV Gardner EE Sandborn WJ Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing Clin Pharmacol Ther 2011 89 387 91 21270794 PMC3098761
  117. [128]Schmiegelow K Al-Modhwahi I Andersen MK Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study Blood 2009 113 6077 84 19224761 PMC2699230
  118. [129]Bhatia S Landier W Shangguan M Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the Children’s Oncology Group J Clin Oncol 2012 30 2094 101 22564992 PMC3601449
  119. [131]Pui CH Howard SC Current management and challenges of malignant disease in the CNS in paediatric leukaemia Lancet Oncol 2008 9 257 68 18308251
  120. [132]Veerman AJ Kamps WA van den Berg H Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004) Lancet Oncol 2009 10 957 66 19747876
  121. [133]Matloub Y Lindemulder S Gaynon PS Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children’s Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children’s Oncology Group Blood 2006 108 1165 73 16609069 PMC1895867
  122. [134]Stumpel DJ Schneider P van Roon EH Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options Blood 2009 114 5490 8 19855078
  123. [135]Bernt KM Zhu N Sinha AU MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L Cancer Cell 2011 20 66 78 21741597 PMC3329803
  124. [136]Hoelzer D Novel antibody-based therapies for acute lymphoblastic leukemia Hematology Am Soc Hematol Educ Program 2011 2011 243 9 22160041
  125. [137]Thomas DA O’Brien S Faderl S Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia J Clin Oncol 2010 28 3880 9 20660823 PMC2940403
  126. [138]Topp MS Kufer P Gokbuget N Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival J Clin Oncol 2011 29 2493 8 21576633
  127. [139]Anderson RM May RM Immunisation and herd immunity Lancet 1990 335 641 45 1969023
  128. [140]Gilham C Peto J Simpson J Day care in infancy and risk of childhood acute lymphoblastic leukaemia: findings from a UK case-control study Br Med J 2005 330 1294 97 15849205 PMC558199
  129. [141]Urayama KY Buffler PA Gallagher ER Ayoob JM Ma X A meta-analysis of the association between day-care attendance and childhood acute lymphoblastic leukaemia Int J Epidemiol 2010 39 718 32 20110276 PMC2878455
  130. [142]Martinelli G Iacobucci I Storlazzi CT IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report J Clin Oncol 2009 27 5202 7 19770381
  131. [143]Kuiper RP Waanders E van der Velden VH IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL Leukemia 2010 24 1258 64 20445578
  132. [144]Bercovich D Ganmore I Scott LM Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down’s syndrome Lancet 2008 372 1484 92 18805579
  133. [145]Gaikwad A Rye CL Devidas M Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia Br J Haematol 2009 144 930 2 19120350 PMC2724897
  134. [146]Kearney L Gonzalez De Castro D Yeung J A specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukaemia Blood 2008 113 646 8 18927438
  135. [147]Cario G Zimmermann M Romey R Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol Blood 2010 115 5393 7 20378752
  136. [148]Pasqualucci L Dominguez-Sola D Chiarenza A Inactivating mutations of acetyltransferase genes in B-cell lymphoma Nature 2011 471 189 95 21390126 PMC3271441
  137. [149]Hijiya N Thomson B Isakoff MS Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia Blood 2011 118 6043 9 21967976 PMC3731655
  138. [150]Dunsmore KP Devidas M Linda SB Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group J Clin Oncol 2012 30 2753 9 22734022 PMC3402886
  139. [151]O’Brien S Schiller G Lister J High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia J Clin Oncol 2012 PMC4979201 23169518
  140. [152]Ottmann OG Larson RA Kantarjian HM Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia Leukemia 2012 23138184
  141. [153]Messinger YH Gaynon PS Sposto R Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study Blood 2012 120 285 90 22653976
  142. [154]Raetz EA Cairo MS Borowitz MJ Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children’s Oncology Group Pilot Study J Clin Oncol 2008 26 3756 62 18669463 PMC2654811
  143. [155]Kantarjian H Thomas D Jorgensen J Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study Lancet Oncol 2012 13 403 11 22357140
  144. [156]Angiolillo AL Yu AL Reaman G Ingle AM Secola R Adamson PC A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children’s Oncology Group report Pediatr Blood Cancer 2009 53 978 83 19637330 PMC3120889
  145. [157]Greaves M Cancer The Evolutionary Legacy Oxford Oxford University Press 2000

Cited by

Sorted by citations

Authors
Inaba, H., Greaves, M., & Mullighan, C. G.
Affiliations
St. Jude Children's Research Hospital (US)
Corresponding author
Inaba, Hiroto
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2013-06
Volume
381
Issue
9881
Pages
1943-1955
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(12)62187-4
PMC
PMC3816716
OpenAlex
W2114340167
Cited by
1,074
References
7
Citations by year
2026: 47 · 2025: 66 · 2024: 53 · 2023: 63 · 2022: 86 · 2021: 76 · 2020: 112 · 2019: 105 · 2018: 82 · 2017: 105 · 2016: 98 · 2015: 91 · 2014: 75 · 2013: 14 · 2012: 1
FWCI
13.25
Type
journal article
Language
en
Open access
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders
National Cancer Institute (CA21765, P30CA021765)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Acute Lymphoblastic Leukemia research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
Keywords
acute lymphoblastic leukemia, pediatric leukemia, leukemogenesis, risk stratification, pharmacogenomics, supportive care, genome-wide characterization, germline mutations, disease subtypes, prognostic factors, personalized medicine, treatment response
MeSH terms
Adolescent, Antineoplastic Agents, Central Nervous System Diseases, Child, Child, Preschool, Chromosome Aberrations, Female, Forecasting, Gene Frequency, Humans, Infant, Male, Prognosis, Recurrence, Remission Induction, Transcription Factors, Translocation, Genetic, Gene Rearrangement, B-Lymphocyte, Genome, Human, Treatment Outcome, Sequence Analysis, DNA, Hematopoietic Stem Cell Transplantation, Risk Assessment, Genetic Predisposition to Disease, Gene Expression Profiling, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review